Two Companies Awarded 2002 Helix Award for Corporate Excellence
New York– (February 21, 2002) – CV Therapeutics and Isis Pharmaceuticals were presented with the seventh Annual Helix Award at the Biotechnology Industry Organization’s CEO & Investor Conference 2002 held at the Waldorf=Astoria Hotel in New York. Isis Pharmaceuticals received the award for the emerging company category, and CV Therapeutics was honored in the large-cap category.
The Helix Award is the highest award of corporate excellence for the international biotechnology industry. The award is presented based on leadership in three distinct areas of scientific innovation, company growth and corporate citizenship. Past winners include OSI Pharmaceuticals, Inc., of Melville, N.Y.; Genentech, Inc., of South San Francisco, Calif.; The Collaborative Group of Stony Brook, N.Y.; Regeneron Pharmaceuticals, Inc., of Tarrytown, N.Y.; Biogen, Inc. of Cambridge, Mass.; and Immunex of Seattle, Wash. These companies have all exemplified the true spirit of corporate leadership in the biotechnology industry.
"Isis has had a tremendous year with the establishment of several pivotal collaborations with industry leaders, major advances in the clinic and accomplishments in our two divisions, GeneTrove and Ibis Therapeutics," said Stanley T. Crooke, M.D., Ph.D., chairman and CEO of Isis. "We are honored that the industry is recognizing the company's achievements and the work of the more than 400 people at Isis."
"I am honored to receive this important award on behalf of my colleagues at CV Therapeutics. This recognition from our peers highlights the critical work that our scientists and clinicians accomplish every day," said Louis G. Lange, M.D., Ph.D., Chairman and CEO of CV Therapeutics. "Our company was founded over ten years ago with a single goal: to find better ways to help patients with cardiovascular disease – still the number one cause of death in the United States. 2001 was highlighted by the positive results from our second pivotal Phase III trial, CARISA, which was presented as a Late Breaking Clinical Trial at the American Heart Association."
The Helix Award is presented by the Long Island Life Sciences Initiative (LILSI) and is jointly sponsored by BIO, Stony Brook University and The Center for Biotechnology.
The Helix Award is open to public and private U.S. or foreign-based biotechnology companies. An independent panel of judges reviewed the 2002 submissions, and KPMG LLP, an international professional services firm tabulated the results.
LILSI is a not-for-profit trade association created to address issues of strategic importance to the biotechnology, pharmaceutical, medical device and life science technology-based industries. LILSI advocates on behalf of public policy that will improve the Long Island region's business climate for life science companies and enhance the research and business infrastructure that is vital to their success. More information on LILSI can be found at www.lilsi.org.
BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. For more information, please visit www.bio.org.